HIGHLIGHTS
- who: Qian Li and colleagues from the Arcellx Inc, United States Saitama Medical University, Japan have published the research work: PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy, in the Journal: (JOURNAL)
- what: The aim of this study was to summarize the mechanism and application of PD-1/PDL-1 checkpoint inhibitors in HCC immunotherapy, and to reflect further on the side effects of treatment, in the hope of developing a promising combination therapy in the future, such that blocking the PD-1/PD-L1 pathway can play a more important role . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.